IL6 is associated with response to dasatinib and cetuximab: Phase II clinical trial with mechanistic correlatives in cetuximab-resistant head and neck cancer

OBJECTIVE: Src family kinase (SFK) activation circumvents epidermal growth factor receptor (EGFR) targeting in head and neck squamous cell carcinoma (HNSCC); dual SFK-EGFR targeting could overcome cetuximab resistance. PATIENTS AND METHODS: We conducted a Simon two-stage, phase II trial of the SFK i...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Oral Oncol
Main Authors: Stabile, L.P., Egloff, A.M., Gibson, M.K., Gooding, W.E., Ohr, J., Zhou, P., Rothenberger, N.J., Wang, L., Geiger, J.L., Flaherty, J.T., Grandis, J.R., Bauman, J.E.
Format: Artigo
Jezik:Inglês
Izdano: 2017
Teme:
Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC5944328/
https://ncbi.nlm.nih.gov/pubmed/28559019
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.oraloncology.2017.03.011
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki